Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FS222 in Advanced Malignancies
NCT04740424Phase 1Active, not recruiting
- Sponsor
- invoX Pharma
- Start
- Dec 2020
- Primary completion
- Oct 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 7
01
Overview
Phase 1, open-label, single-arm trial of FS222 in solid tumor, sponsored by invoX Pharma. Primary endpoints: Presence of adverse events (AEs) and serious adverse events (SAEs) at 15 months, Maximum Tolerated Dose at 28 days and 1 more. Started Dec 2020; status: active, not recruiting.
02
Drugs
FS222
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04740424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04740424.